Senseonics' Eversense® E3 CGM Now Covered by UnitedHealthcare for Adults with Diabetes
Senseonics, a medical technology company, has recently announced that UnitedHealthcare will now provide coverage for the Eversense® E3 Continuous Glucose Monitoring (CGM) system for adults living with diabetes. This development allows UnitedHealthcare members to access and benefit from the advanced CGM technology offered by Eversense® E3.
The Eversense® E3 CGM system is designed to help individuals with diabetes manage their condition more effectively. It consists of an implantable sensor that is placed under the skin, a transmitter, and a mobile app. The sensor continuously measures glucose levels in the interstitial fluid, providing real-time readings to the user via the app. The Eversense® E3 CGM system offers several advantages, including a long sensor life of up to 90 days, eliminating the need for frequent sensor insertions.
By partnering with UnitedHealthcare, Senseonics aims to expand access to this innovative CGM technology for individuals with diabetes who are covered by UnitedHealthcare insurance. The coverage of Eversense® E3 by UnitedHealthcare will enable eligible adults to enjoy the benefits of continuous glucose monitoring, such as improved glycemic control, enhanced hypoglycemia detection, and greater convenience in managing their diabetes.
This announcement reflects a positive step toward improving diabetes management and empowering individuals to make more informed decisions about their health. By integrating advanced technology like the Eversense® E3 CGM system into healthcare coverage, individuals with diabetes can access tools that support better glucose control and ultimately enhance their overall quality of life.
The coverage of the Eversense® E3 CGM system by UnitedHealthcare signifies a significant milestone in the adoption of advanced diabetes management technologies. Continuous glucose monitoring has become increasingly recognized as a valuable tool in helping individuals with diabetes monitor their glucose levels in real-time and make timely adjustments to their treatment plans.
The Eversense® E3 CGM system offers several features that set it apart from traditional CGM systems. Its implantable sensor provides accurate and reliable glucose readings, reducing the need for frequent fingerstick tests. The sensor can be worn for up to 90 days, providing an extended monitoring period compared to other CGM systems, which typically require sensor changes every 7-14 days. This longer sensor life can improve convenience for individuals with diabetes, minimizing interruptions in their daily routines.
Moreover, the system integrates with a mobile app that offers comprehensive data management and analysis tools. Users can easily access their glucose trends, receive real-time alerts for high or low glucose levels, and share data with their healthcare providers for more effective diabetes management. This connectivity empowers individuals to take a more proactive role in their care and collaborate with their healthcare team to make informed decisions.
The coverage of the system by UnitedHealthcare demonstrates a growing recognition of the value that advanced diabetes technologies bring to individuals managing their condition. By providing coverage for this innovative CGM system, UnitedHealthcare is helping to ensure that its members with diabetes have access to the latest advancements in glucose monitoring technology, ultimately promoting better health outcomes and improved quality of life.
It is anticipated that the expanded coverage of the Eversense® E3 CGM system by UnitedHealthcare will pave the way for increased acceptance and adoption of CGM technology among other insurance providers, making it more accessible to a broader population of individuals living with diabetes.
The Eversense® E3 CGM system is designed to help individuals with diabetes manage their condition more effectively. It consists of an implantable sensor that is placed under the skin, a transmitter, and a mobile app. The sensor continuously measures glucose levels in the interstitial fluid, providing real-time readings to the user via the app. The Eversense® E3 CGM system offers several advantages, including a long sensor life of up to 90 days, eliminating the need for frequent sensor insertions.
By partnering with UnitedHealthcare, Senseonics aims to expand access to this innovative CGM technology for individuals with diabetes who are covered by UnitedHealthcare insurance. The coverage of Eversense® E3 by UnitedHealthcare will enable eligible adults to enjoy the benefits of continuous glucose monitoring, such as improved glycemic control, enhanced hypoglycemia detection, and greater convenience in managing their diabetes.
This announcement reflects a positive step toward improving diabetes management and empowering individuals to make more informed decisions about their health. By integrating advanced technology like the Eversense® E3 CGM system into healthcare coverage, individuals with diabetes can access tools that support better glucose control and ultimately enhance their overall quality of life.
The coverage of the Eversense® E3 CGM system by UnitedHealthcare signifies a significant milestone in the adoption of advanced diabetes management technologies. Continuous glucose monitoring has become increasingly recognized as a valuable tool in helping individuals with diabetes monitor their glucose levels in real-time and make timely adjustments to their treatment plans.
The Eversense® E3 CGM system offers several features that set it apart from traditional CGM systems. Its implantable sensor provides accurate and reliable glucose readings, reducing the need for frequent fingerstick tests. The sensor can be worn for up to 90 days, providing an extended monitoring period compared to other CGM systems, which typically require sensor changes every 7-14 days. This longer sensor life can improve convenience for individuals with diabetes, minimizing interruptions in their daily routines.
Moreover, the system integrates with a mobile app that offers comprehensive data management and analysis tools. Users can easily access their glucose trends, receive real-time alerts for high or low glucose levels, and share data with their healthcare providers for more effective diabetes management. This connectivity empowers individuals to take a more proactive role in their care and collaborate with their healthcare team to make informed decisions.
The coverage of the system by UnitedHealthcare demonstrates a growing recognition of the value that advanced diabetes technologies bring to individuals managing their condition. By providing coverage for this innovative CGM system, UnitedHealthcare is helping to ensure that its members with diabetes have access to the latest advancements in glucose monitoring technology, ultimately promoting better health outcomes and improved quality of life.
It is anticipated that the expanded coverage of the Eversense® E3 CGM system by UnitedHealthcare will pave the way for increased acceptance and adoption of CGM technology among other insurance providers, making it more accessible to a broader population of individuals living with diabetes.
contact details:
If you have any investor-related inquiries or need further information about Senseonics, you can contact Philip Taylor, who handles Investor Relations. You can reach him at 415-937-5406 or via email at investors@senseonics.com. Philip Taylor will be able to assist you with any questions or concerns regarding Senseonics' investor relations.
Comments
Post a Comment